Imperial Oil Limited Common Stock vs Regeneron Pharmaceuticals Inc — how do they compare? Imperial Oil Limited Common Stock trades at $129.6 (market cap $62.22B), while Regeneron Pharmaceuticals Inc trades at $784.4 (market cap $77.54B). The key difference: Regeneron Pharmaceuticals Inc is the larger of the two by market cap, and Imperial Oil Limited Common Stock pays the higher dividend (1.9%). Which is the better fit depends on your goals.
| IMO | REGN | |
|---|---|---|
Market Cap | $62.22B | $77.54B |
Volume | 560,544 | 629,519 |
Sector | Energy | Health |
52-Week High | $138.33 | $852.03 |
52-Week Low | $83.72 | $569.17 |
Enterprise Value | $63.13B | $72.25B |
Dividend Yield | 1.9% | 0.5% |
Typical Hold Time | — | 107 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Regeneron Pharmaceuticals (REGN) trades at $778.36, up 2.04% on the day, with a bullish technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Recent news highlights a significant expansion of its immunology alliance with Sanofi, valued up to $8 billion, which could drive future growth. Valuation ratios appear reasonable, with a P/E of 18.64 and robust profitability margins.
The outlook for REGN is positive, supported by strong earnings momentum, a lucrative partnership expansion, and a unanimous analyst buy consensus. Key risks include competitive pressures in the biopharma space and reliance on key drug performance. The stock presents a compelling opportunity for growth investors, with a consensus price target of $849.84 suggesting upside potential.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Imperial Oil Limited is a Canadian integrated energy company that explores for and produces crude oil and natural gas, operates oil sands projects at Cold Lake, Kearl, and Syncrude, and refines and markets petroleum products under the Esso and Mobil brands. ExxonMobil Corporation holds a majority ownership stake in the company.
Read more on IMO →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →